A Combination of Pharmacophore Modeling, Molecular Docking and Virtual Screening Study Reveals 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-Chromen-4-One as a Potential Anti-Cancer Agent of COT Kinase

Afzal Hussain*, Chandan Kumar Verma

Department of Bioinformatics, MANIT, Bhopal, Madhya Pradesh, INDIA.

ABSTRACT

Background: COT (Tpl2/MAP3K8) is a Serine/Threonine protein kinase which plays a crucial role in the production of TNF-alpha through the phosphorylation of MEK, ERK pathway and the production of other pro-inflammatory cytokines. Its inhibition has been shown as important to reduce inflammatory diseases and cancer. Material and Methods: Combined Ligand-based and Structure-based pharmacophore model was developed for finding out the potential anticancer agents. These combined pharmacophore model was used as 3D-query for searching the matching pharmacophore features against chemical structure databases such as DrugBank, MDPI, ZINC, Maybridge HitFinder. Docking was performed using Schrodinger software as well as selected Hits were filtered by ADMET properties. Results: Among all the selected Hits Compound 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one was found to be more potent according to the docking score. Conclusion: A step by step computational pipeline was used to find out the potential anticancer agents. This study suggests that these Hits could be used as anticancer agents against death leading diseases.

Key words: COT Kinase, Docking, Pharmacophore model, Anticancer, LigandScout.

INTRODUCTION

Protein kinases shows its important role in the cellular functioning process. They take part in the various processes such as transcription, cell division, controlling the metabolism, cell movement, immune response, nervous system functioning. Kinase dysfunction is related to many diseases like cancer as well as inflammatory. The COT (Cancer Osaka Thyroid Kinase) kinase is a Mitogen Activated Protein Kinase 8 (MAP3K8). In the unstimulated cells, it makes a heterotrimetric complex with NF-kB-1 precursor protein p105 and the ubiquitin-binding protein ABIN-2, when stimulation came with various inflammatory stimuli like Lipopolysaccharide (LPS), TNF-receptor 1, TNF, CD40 ligand through Toll-Like Receptors (TLRs), CD40 and interleukin receptor (IL-1), it activates IKKB, which triggers the proteasomal degradation of the p105 and releases the ABIN-2 from the association of the p105 and COT. Activation of the COT involve to regulate various downstream inflammatory pathways including ERK, MEK, JNK, p384-7 (Figure 1).

After a vast literature survey it has been confirmed the role of the COT kinase in diverse diseases like high grade serious ovarian carcinoma, Acetaminophen-induced liver injury, Adipose tissue dysfunction in obesity, Breast cancer, Pancreatic and lung inflammation during acute pancreatitis.
Metastasis of clear cell renal cell carcinoma, Obesity induced adipose tissue inflammation, Papillary thyroid cancer, Multiple sclerosis. There are so many inhibitors have been identified to reduce the harmful effect of the COT kinase such as (E)-3-(2-amino-5-(naphthalen-2-yl)pyridin-3-yl)acrylic acid, 5-(5-(1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3,4-oxadiazol-2-amine, 5-(2-amino-5-(quinolin-3-yl)pyridin-3-yl)-1,3,4-oxadiazole-2(3H)-thione, 4-alkylamino-(1,7) naphthyridine-3-carbonitriles, Indazoles, 1,7-naphthyridine-3-carbonitriles, thieno (2,3-c) pyridine, 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles.

So there is a need to find out the small molecule cancer drugs. The main aim of this study to design a systematic approach for the discovery of novel inhibitors searching out of Drug Databases. Ligand Based and Structure-based Pharmacophore model was generated with the help of LigandScout 3.12 and Schrodinger Software. This Pharmacophore model was used as 3-D query to search novel inhibitory compounds using diverse databases like ZINC, DrugBank, MDPI, Maybridge HitFinder. After getting the selected Hits, were subjected for the docking studies. 10 top Hits were identified, among them only four hits shows best characteristics and docking score more than previous reported compound. Compound (Hit 1) 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one was found as most potent compound may be further used in the designing a new scaffold lead-like molecule for COT kinase inhibition.

**MATERIALS AND METHODS**

**The Generation of the Ligand-Based Pharmacophore Model**

The common features based pharmacophore model was developed using three best Co-crystallized ligand found in the protein data bank in the complex form with the target. LigandScout (two training and one test ligand pharmacophore) and Schrodinger software tool (one ligand pharmacophore) was used, which develop the pharmacophore model in the most appropriate way. This Pharmacophore model was used as 3D query for searching out the matching pharmacophore Hits from diverse databases [DrugBank, MDPI, ZINC, Maybridge HitFinder]. The model was represented in Figure 2.

**Generation of Structure-Based Pharmacophore model**

The Structure-Based pharmacophore model was generated using the Protein (PDBID: 4Y83). The protein structure was downloaded which contain the Ligand. The ligand-protein interaction residues chemical features were selected. We applied LigandScout 3.12 software for generating the pharmacophore model which contain all the chemical features information such as Hydrogen bond donors, Hydrogen bond acceptors, Hydrophobic residues within the binding site sphere of the receptors. It was shown in Figure 3.

**Pharmacophore Feature Matching Screening**

Drug database screening is a very crucial Bioinformatics technique for the drug discovery process in the medicinal chemistry research. We developed Ligand based and
Structure based pharmacophore model, subjected against the commercially existing databases using LigandScout and Schrodinger software (Phase module) for Matching the pharmacophore features with the drug databases available drugs.20,24,45

**Ligand-Protein preparation and Docking**

**Protein Preparation**

The target protein structure with inhibitor (PDBID: 4Y83) was downloaded from Protein data bank. Schrodinger software Prep wizard was used to prepare the structure, where bond orders were assigned and hydrogen atoms were added and in the last stage of preparation, restrained minimization was performed with OPLS-2005 force field and RMSD cut off was kept as 0.30 \( \text{Å} \).20

**Ligand Preparation**

Pharmacophore matched Hits were retrieved and exported as .sdf file and prepared by using LigPrep module of the Schrodinger software. In the preparation process the bond angle and the bond order were assigned. The minimization was done using OPLS-2005 force field and used Epik option for keeping ligand in the correct protonation state.46

**Grid Preparation**

The grid of the selected target structure was prepared by using the Glide protocol of the Schrodinger software. The crystallized inhibitor binding site was selected as centroid for the COT kinase and partial charge cutoff was kept as 0.25. The scaling factor was chosen as 1.0 correspondingly.47

**Preparation of the Reference Compound**

The Crystallized inhibitor with the target was retrieved from the PDB (PDBID:4Y83). The inhibitor was also prepared by using the LigPrep module of the Schrodinger software and docked with the COT kinase to find out the binding interaction and docking score, which can be use further as reference score for finding out the potential Hits form MDPI, DrugBank, ZINC and Maybridge HitFinder databases.

**Docking**

The selected pharmacophore features matching Hits were further subjected for docking using Glide maestro virtual screening protocol. These selected compounds were filtered by Lipinski rule. The pre-reported inhibitor (reference compound) was also incorporated with these compounds. The docking (virtual screening workflow) was performed using HTVS, SP and XP steps against the target protein.41 The workflow was shown in Figure 4.

**RESULTS AND DISCUSSION**

**Pharmacophore Feature Matching Screening and Docking against the Target**

Novel Hits were identified by using the Pharmacophore feature matching screening and docking. Diverse drug databases like [MDPI, DrugBank, ZINC, Maybridge HitFinder] were used for getting the Hits. Ligand based and Structure based generating Pharmacophore model, which was further used as a 3D-query for screening against the drug databases. A limited number of potential Hits were identified, showed features like pharmacophore model. All the selected Hits were incorporated in the Schrodinger software for docking. Total 4 potential specific Hits were identified which showed best binding
interaction with the target protein. Hit 1, 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one was found as a most potent Hit, showed interaction with the active binding site of the target protein. It showed Hydrogen bond interaction with the residues (GLU 208, GLY 210, LYS 133, SER 214), Pi-Pi stacking with TRP 132 and the docking score is (-12.349). The docking score is high, first Hit showed tight interaction with the target with good inhibition characteristics. The docking score for all the selected Hits were identified (Table 1).

Docking with LigPlot interaction diagram gives a better presentation of binding between the target and the Hit compounds (Figure 5).

**Drug-likeliness property analysis**

Drug like features (Lipinski’s rule of five) of the selected best Hits were confirmed using Drug-likeliness property analysis. A good drug is always contain properties such as well distributed throughout the system, absorbed in the timeline as well as shows good metabolism property. QikProp tool of the Schrodinger software was used for this study. We have selected some properties which always give more impact like Human Oral Absorption, Molecular Weight (MW), Hydrogen bond donor (HBD), Hydrogen bond acceptor (HBA), Total Solvent Accessible Surface, Predicted Aqueous Solubility (QP log S). Additional Properties were also identified like Predicted Polarizability (QPpolrz), Total Solvent Accessible Surface Area (SASA), Predicted octanol/water partition coefficient (QPlogPo/w), Predicted hexadecane/gas partition coefficient (QPlogPC16), Predicted octanol/gas partition coefficient (QPlogPoct), Predicted water/gas partition coefficient (QPlogPw), Prediction of binding to human serum albumin (QPlogKhsa), Predicted skin permeability (QPlogKp), Lower the value of molecular weight is one of the favorable characteristics for drug like properties.

Total four potential Hits with their Drug-like properties were presented in Table 2.

**ADMET Prediction for selected screened Hits**

ADMET prediction for selected best Hits were performed using admetSAR server. BBB probability, Caco-2 probability as well as HIA probability indicates good value where BBB represents the blood brain barrier, Higher the value of BBB represent better penetration, HIA (Human intestinal absorption) score is high shows better absorbance in the intestinal tract upon oral administration. Hits were mutagenic or not was confirmed by AMES test. Table 3. Prediction the efflux by P-glycoprotein (P-gp) metabolism of the selected best Hit compounds were carried out by a family of microsomal enzymes CYP-3A4, CYP-2C9, CYP-1A2 and CYP-2C19 shown in Table 4.

**Superimpose Structure**

Superimpose is a way where we can identify that the selected best Hits occupied the same binding sites or not. All the selected best Hits were superimposed and we found that the binding patterns were similar to the active site crystallized inhibitor.

**CONCLUSION**

A step by step computational pipeline was used to find out the potential anticancer agents. Ligand and structure based pharmacophore model was developed as 3-D query and Drugbank, MDPI, ZINC, Maybridge HitFinder drug databases were subjected for the screening process against the target (COT kinase) in a very rapid manner and docking was performed using Schrodinger software. Drug likeliness analysis, ADMET analysis was done with the help of admetSAR and QikProp. Total 4 best Hits were found promising and showed potential inhibitory characteristics. Hit 1, 3,5,7-trihydroxy-2-(3,4,5-
<table>
<thead>
<tr>
<th>Compound</th>
<th>Compound Structure</th>
<th>Mol. Wt.</th>
<th>Mol. Formula</th>
<th>Docking Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hit 1</td>
<td><img src="image1" alt="Structure" /></td>
<td>318.235</td>
<td>C₁₅H₁₀O₈</td>
<td>-12.349</td>
</tr>
<tr>
<td>Hit 2</td>
<td><img src="image2" alt="Structure" /></td>
<td>302.236</td>
<td>C₁₅H₁₀O₇</td>
<td>-11.839</td>
</tr>
<tr>
<td>Hit 3</td>
<td><img src="image3" alt="Structure" /></td>
<td>314.273</td>
<td>C₁₅H₁₂N₂O₅</td>
<td>-11.330</td>
</tr>
<tr>
<td>Hit 4</td>
<td><img src="image4" alt="Structure" /></td>
<td>298.274</td>
<td>C₁₅H₁₀N₂O₄</td>
<td>-11.258</td>
</tr>
<tr>
<td>Hit 5</td>
<td><img src="image5" alt="Structure" /></td>
<td>362.425</td>
<td>C₂₁H₂₂N₄O₂</td>
<td>-10.796</td>
</tr>
<tr>
<td>Hit 6</td>
<td><img src="image6" alt="Structure" /></td>
<td>250.28</td>
<td>C₁₀H₁₆N₇O⁺</td>
<td>-10.782</td>
</tr>
<tr>
<td>Hit 7</td>
<td><img src="image7" alt="Structure" /></td>
<td>312.301</td>
<td>C₁₈H₁₂N₂O₄</td>
<td>-10.620</td>
</tr>
<tr>
<td>Hit 8</td>
<td><img src="image8" alt="Structure" /></td>
<td>284.263</td>
<td>C₁₈H₁₂O₆</td>
<td>-10.493</td>
</tr>
<tr>
<td>Hit 9</td>
<td><img src="image9" alt="Structure" /></td>
<td>312.317</td>
<td>C₁₈H₁₆O₅</td>
<td>-10.388</td>
</tr>
<tr>
<td>Hit 10</td>
<td><img src="image10" alt="Structure" /></td>
<td>328.316</td>
<td>C₁₈H₁₆O₆</td>
<td>-10.319</td>
</tr>
<tr>
<td>5-(2-amino-5-(quinolin-3-yl) pyridin-3-yl)-1,3,4-oxadiazole-2(3H)-thione</td>
<td><img src="image11" alt="Structure" /></td>
<td>--</td>
<td>--</td>
<td>-11.1403</td>
</tr>
</tbody>
</table>

r=Reference ligand
Table 2: Drug-like properties analysis of the selected best Hits.

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Compound Ida</th>
<th>Mol. Wt.b</th>
<th>SASAc</th>
<th>Human Oral Absorptiond</th>
<th>HB donorf</th>
<th>HB acceptorf</th>
<th>QP log Sg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Hit 1</td>
<td>318.235</td>
<td>527.917</td>
<td>26.816</td>
<td>5</td>
<td>6</td>
<td>-2.635</td>
</tr>
<tr>
<td>2.</td>
<td>Hit 2</td>
<td>302.236</td>
<td>515.473</td>
<td>51.557</td>
<td>4</td>
<td>5</td>
<td>-2.852</td>
</tr>
<tr>
<td>3.</td>
<td>Hit 3</td>
<td>314.273</td>
<td>541.307</td>
<td>57.245</td>
<td>2</td>
<td>8</td>
<td>-2.855</td>
</tr>
<tr>
<td>4.</td>
<td>Hit 4</td>
<td>298.274</td>
<td>558.556</td>
<td>57.595</td>
<td>2</td>
<td>8</td>
<td>-3.481</td>
</tr>
</tbody>
</table>

aCompound  
bMolecular weight (acceptable range is: ≤500)  
cTotal solvent accessible surface area (acceptable range is: 300-1000)  
dHuman oral absorption (acceptable range is:<25% less and >80% high)  
eHydrogen bond donor (acceptable range is: ≤5)  
fHydrogen bond acceptor (acceptable range is:≤10)  
gPredicted aqueous solubility (acceptable range is: -6.5-0.5)

Table 3: In-Silico absorption and toxicity analysis using admetSAR server.

<table>
<thead>
<tr>
<th>S.No.</th>
<th>Compound</th>
<th>BBB Probability</th>
<th>HIA Probability</th>
<th>Caco-2 Probability</th>
<th>AMES Test</th>
<th>Carcinogenicity</th>
<th>Rat acute toxicity (LD50:mol/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Hit 1</td>
<td>0.5711</td>
<td>0.9650</td>
<td>0.8957</td>
<td>Non-toxic</td>
<td>Non-carcinogens</td>
<td>3.0200</td>
</tr>
<tr>
<td>2.</td>
<td>Hit 2</td>
<td>0.5711</td>
<td>0.9650</td>
<td>0.8957</td>
<td>Non-toxic</td>
<td>Non-carcinogens</td>
<td>3.0200</td>
</tr>
<tr>
<td>3.</td>
<td>Hit 3</td>
<td>0.7307</td>
<td>0.9768</td>
<td>0.5801</td>
<td>toxic</td>
<td>Non-carcinogen</td>
<td>2.4586</td>
</tr>
<tr>
<td>4.</td>
<td>Hit 4</td>
<td>0.8169</td>
<td>0.9878</td>
<td>0.6126</td>
<td>Non-toxic</td>
<td>Non-carcinogens</td>
<td>2.3709</td>
</tr>
</tbody>
</table>

Table 4: Prediction the efflux by P-glycoprotein (P-gp) metabolism of the best Hit compounds.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Hit 1</td>
<td>substrate/ Non-Inhibitor</td>
<td>Non-substrate/ Non-Inhibitor</td>
<td>Non-substrate/ Non-Inhibitor</td>
<td>Inhibitor</td>
<td>Non-Inhibitor</td>
<td>High</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>Hit 2</td>
<td>substrate/ Non-Inhibitor</td>
<td>Non-substrate/ Non-Inhibitor</td>
<td>Non-substrate/ Non-Inhibitor</td>
<td>Inhibitor</td>
<td>Non-Inhibitor</td>
<td>High</td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td>Hit 3</td>
<td>Non-substrate/ Non-Inhibitor</td>
<td>Non-substrate/ Non-Inhibitor</td>
<td>Non-substrate/ Non-Inhibitor</td>
<td>substrate/ Inhibitor</td>
<td>Inhibitor</td>
<td>High</td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td>Hit 4</td>
<td>Non-substrate/ Non-Inhibitor</td>
<td>Non-substrate/ Non-Inhibitor</td>
<td>Non-substrate/ Non-Inhibitor</td>
<td>substrate/ Inhibitor</td>
<td>Inhibitor</td>
<td>Non-Inhibitor</td>
<td>High</td>
</tr>
</tbody>
</table>
trihydroxyphenyl)-4H-chromen-4-one) was found most potent and selective and showing better interaction as well as high docking score. This study suggests that these Hits could be used as anticancer agents against death leading diseases.

**CONFLICT OF INTEREST**
The authors declare no conflict of interest.

**ABBREVIATIONS**


**REFERENCES**

About Authors

**Afzal Hussain** working as a Ph.D. Research Scholar in NIT, Bhopal. He worked in the field of medicinal chemistry using a bioinformatics approach for searching out novel anticancer agents as well as using advanced next-generation sequencing for analysis cancer gene expression. He has more than nine years experience in this field, in which he has found novel compounds for the specific kinases for reducing harmful death-leading effects. Afzal is currently collaborating with many organizations to design anti-inflammatory molecules against cancer. He has received the prestigious Young Scientist Award and has twice been the recipient of the Young Scientist Fellowship from the Ministry of Science and Technology, India, for showing their best involvement in research work. He has also worked in the Ministry of Science and Technology in Junior Research Fellow projects. His scientific work has been published in high impact journals including the European Journal of Medicinal Chemistry, Biomedical Research and the SJBC. His areas of expertise include bioinformatics, drug designing, next-generation sequencing data analysis, and phylogenetic analysis.

**Dr. Chandan Kumar Verma** is working as an Assistant Professor in M.A.N.I.T., Bhopal. He is having 15 years experience and 21 international publication in the reputed journals. He is having vast experience in the field of Bioinformatics data analysis, Microarray gene expression etc.

**Cite this article:** Hussain A, Verma CK. A Combination of Pharmacophore Modeling, Molecular Docking and Virtual Screening Study Reveals 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-Chromen-4-One as a Potential Anti-Cancer Agent of COT Kinase. Indian J of Pharmaceutical Education and Research. 2018;52(4):699-706.